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STING modulates immunity by responding to bacterial and endogenous cyclic dinucleotides (CDNs). Humans
and mice with STING gain-of-function mutations develop a syndrome known as STING-associated vasculop-
athy with onset in infancy (SAVI), which is characterized by inflammatory or fibrosing lung disease. We hypoth-
esized that hyperresponsiveness of gain-of-function STING to bacterial CDNs might explain autoinflammatory
lungdisease in SAVImice.We report that depletion of gutmicrobeswith oral antibiotics (vancomycin, neomycin,
and ampicillin [VNA]) nearly eliminates lung disease in SAVI mice, implying that gut microbes might promote
STING-associated autoinflammation. However, we show that germ-free SAVI mice still develop severe autoin-
flammatory disease and that transferring gutmicrobiota fromantibiotics-treatedmice to germ-free animals elim-
inates lung inflammation. Depletion of anaerobes with metronidazole abolishes the protective effect of the VNA
antibiotics cocktail, and recolonization with the metronidazole-sensitive anaerobe Bacteroides thetaiotaomi-
cron prevents disease, confirming a protective role of a metronidazole-sensitive microbe in a model of SAVI.
INTRODUCTION
Stimulator of interferon genes (STING) regulates immune re-
sponses to bacteria and viruses by responding to cyclic dinucle-
otides (CDNs), including the endogenous STING ligand 2030-cyclic
GMP-AMP (cGAMP) that is produced by cyclic GMP-AMP syn-
thase (cGAS) (Sun et al., 2013). Bacteria also produce STING-acti-
vating CDNs, including c-di-GMP, c-di-AMP, and 3030-cGAMP
(Davies et al., 2012). Humans and mice with gain-of-function mu-
tations in STING develop spontaneous inflammation in the lungs,
hypercytokinemia, and T cell cytopenia (Liu et al., 2014; Warner
et al., 2017). BecauseSTINGgain-of-functionmutantsmay exhibit
enhanced ligand sensitivity (Liu et al., 2014), we reasoned that
CDNs produced by commensal bacteria might regulate autoim-
mune lung disease pathogenesis in a mouse model of STING-
associated vasculopathy with onset in infancy (SAVI).
STING responds to CDNs by activating the type I interferon (IFN)
response. Bacterial CDNswere first described nearly 30 years ago
(Ross et al., 1990) and can act as second messengers to regulate
bacterial processes such as biofilm formation, virulence, antibiotic
production, and other physiological processes (Ahmad et al.,
2020; Nuzzo et al., 2020; Tang et al., 2016). In addition to activating
the type I IFN response, CDNs are broadly immunostimulatory
molecules that regulate innate and adaptive immunity (Elahi
et al., 2014; Karaolis et al., 2007). Due to their immunostimulatory
properties, CDNs have been studied extensively as adjuvants for
vaccines and were effective in preclinical studies as cancer immu-
notherapy (Chandra et al., 2014; Fu et al., 2015; Nakamura et al.,
2015). However, less is known about the role of bacterial and
endogenous CDNs in autoimmune diseases, including those
caused by gain-of-function mutations in STING.
The mammalian gastrointestinal tract is colonized by trillions
of commensal bacteria, more in number and in species diversity
than any other region of the body (Peterson et al., 2009; Savage,
1977). These commensal bacteria serve multiple functions that
benefit the host, including facilitation of nutrient metabolism
and other aspects of digestion (Hooper et al., 2002) and develop-
ment of gut-associated lymphoid tissue (Lanning et al., 2000).
Notably, gut bacteria and their metabolites canmodulate allergic
lung disease in mice (Trompette et al., 2014). Unlike models of
asthma or allergic airway inflammation, SAVI mice develop in-
flammatory lung disease with perivascular immune cell infiltra-
tion (Warner et al., 2017). Whether gut microbes play a role in
SAVI-associated lung disease was not previously studied.
Here, we report that gut anaerobes canmodulate autoinflamma-
tory lung disease in a mouse model of SAVI. Treatment of SAVI
micewith an antibiotic cocktail, which spares somegut anaerobes,
led to near-complete protection against lung disease in SAVI mice.
Metagenomic sequencing revealed species of Bacteroidales,
includingMuribaculum and Bacteroides, in animals that were pro-
tected against systemic autoimmunity. Protection against autoim-
munity was eliminated by adding the antibiotic metronidazole,
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which acts on anaerobic bacteria. The immunoprotective effects of
gut anaerobes were transferrable to germ-free animals that other-
wise develop severe autoinflammatory lung disease even in germ-
free conditions. Furthermore, recolonization of microbe-depleted
animals with Bacteroides thetaiotaomicron (B. theta) prevents
autoinflammatory lung disease in SAVI mice, suggesting a role
for specific commensal bacteria in regulating autoinflammatory
lung disease. Our findings may lead to further studies of
microbe-host interactions in SAVI patients.
RESULTS
Bone-marrow-derived macrophages (BMDMs) from
SAVI mice are hyperresponsive to a bacterial CDN
We previously found that SAVI mice develop perivascular inflam-
mation in the lung, but not airway disease (Warner et al., 2017).
The perivascular lung pathology develops independently of
cGAS, suggesting that the endogenous STING ligand cGAMP is
not required to initiate disease (Luksch et al., 2019). Because
STING also detects bacterial CDN ligands (Burdette et al.,
2011), we hypothesized that STING N153S BMDMs might exhibit
enhanced responses to a bacterial CDN. To test this hypothesis,
we performed a dose-response experiment by transfecting wild-
type (WT) and STING N153S BMDMs with c-di-GMP. We found
that transfection with c-di-GMP results in a 2- or 3-fold higher
expression of interferon-stimulated genes (ISGs) in STING
N153S BMDMs compared with WT control cells (Figures 1A and
1B), suggesting that the STING mutant is hyperresponsive to a
bacterial CDN. STING signaling in antigen-presenting cells can
cause upregulation of major histocompatibility complex (MHC)
class II (Karaolis et al., 2007), but the impact of STINGgain of func-
tion on MHC class II expression was not previously tested. In
BMDMs, STING gain of function was associated with higher
MHC class II expression at baseline and, in response to c-di-
GMP, a1.5-fold increase inMHCclass II upregulation compared
with WT BMDMS (Figures 1C–1E). In contrast, MHC class II was
not upregulated in response to c-di-GMP in STING Goldenticket
(GT) BMDMs, which lack functional STING signaling (Figures
1C–1E). Similarly, the costimulatory molecule CD86 was upregu-
lated in both WT and STING N153S cells, but not in STING GT
macrophages (Figure 1F). In contrast, CD80 expression was not
impacted by c-di-GMP under these conditions (Figure 1G).
Collectively, these results demonstrate that theSTINGN153Smu-
tation renders BMDMsmore responsive to c-di-GMP stimulation.
Treatment with an antibiotic cocktail nearly eliminates
lung disease in SAVI mice
Because STING N153S BMDMs are more responsive to bacte-
rial c-di-GMP, we reasoned that commensal bacteria may
contribute to spontaneous autoimmunity and lung disease in
SAVI mice. To test our hypothesis that bacteria contribute to
perivascular lung inflammation in our model of SAVI, we
Figure 1. STING N153S gain-of-function bone-marrow-derived macrophages (BMDMs) are hyper-responsive to cyclic di-GMP, a bacterial
cyclic dinucleotide
BMDMs were isolated from WT, STING N153S (SAVI), or STING Goldenticket mice following stimulation with cyclic di-GMP or control.
(A and B) Gene expression levels of IFIT1 and ISG15 were measured in WT and STING N153S BMDMs.
(C–G) Geometric mean of (C and D) MHC class II, (E) MHC class I, (F) CD86, and (G) CD80 on WT, STING N153S, or STING Goldenticket mice was measured by
flow cytometry following stimulation with cyclic di-GMP or control.
Data represent the mean ± SEM of 4 biological replicates per group, which were pooled from 2 independent experiments. Results were analyzed by Mann-
Whitney test. *p < 0.05; **p < 0.01.




administered an antibiotic cocktail of vancomycin, neomycin,
and ampicillin (VNA) to 4-week-old co-housed WT and SAVI
mice. Treatment with VNA antibiotics almost completely elimi-
nated histological evidence of lung disease in SAVI animals
(Figures 2A and 2B). Treatment of mice for 4 weeks and subse-
quent removal of antibiotics led to recurrence of lung disease,
suggesting a need for continuous depletion of microbes to pre-
vent lung disease (Figure S1).
Figure 2. Treatment with the vancomycin,
neomycin, and ampicillin (VNA) antibiotics
cocktail reduces perivascular inflammation
and ISGs in the lungs of SAVI mice
Four-week-old STING N153S (SAVI) mice were
administered VNA cocktail or vehicle control ad li-
bitum and euthanized at age 12 weeks.
(A) Representative hematoxylin and eosin-stained
images of lung sections from age-matched 12-
week-old STING N153S mice and littermate control
mice. Top panel images were taken under low
magnification, and bottompanel imageswere taken
under high magnification. Scale bars: 100 mm.
(B) Quantitation of affected lung area of STING
N153S mice following administration of VNA or
control.
(C–E) 16S analysis on stool samples collected from
12-week-old, co-housed WT and STING N153S lit-
termates.
(F–K) Gene expression of ISGs, cytokines, and che-
mokines following administration of VNA or control.
Data represent themean±SEMof n= 5–13miceper
genotype pooled from 3 independent experiments.
Results were analyzed by Mann-Whitney test. *p <
0.05; ***p < 0.001.
Because various bacteria differentially
produceCDNs in response to phages (Co-
hen et al., 2019), we reasoned that differ-
ences inmicrobial populationsmayexplain
the effect of antibiotics on lung disease. To
begin to characterize the gut microbiota of
our animals, we performed 16S and phag-
eome analysis of fecal samples from co-
housed WT and SAVI mice. Treatment
with the VNA antibiotics cocktail almost
completely depleted the gut of bacteria
based on 16S analysis (Figure 2C),
although Bacteroides species remained
detectable byPCR (data not shown). In un-
treated, co-housed WT and SAVI animals,
mouse genotype hadno effect onbacterial
richness or diversity (Figures 2D, 2E, and
S2A). Furthermore, virome analysis re-
vealed similar bacteriophage composi-
tions in co-housedWTandSAVImice (Fig-
ures S2B–S2E).
Levels of pro-inflammatory cytokines,
chemokines, and ISGs are elevated in the
lungs of SAVI mice (Luksch et al., 2019).
Treatment with VNA antibiotics caused a
2-fold reduction in Isg15 and a 4-fold reduction in Cxcl10
expression in the lungsofSAVImicecomparedwithWTcontrol an-
imals (p < 0.05) (Figures 2F–2K). In addition to almost completely
eliminating histological evidence of lung disease (Figures 2A and
2B), multiplex cytokine analysis of lung homogenates revealed
that pro-inflammatory cytokine and chemokine levels were re-
turned to levels of healthy WT control mice (Figures 3A–3C).
Thus, antibiotics can eliminate autoinflammatory lung disease in




SAVImice, but thisprotectiveeffect requirescontinuous treatment
with antibiotics.
Treatment with oral antibiotics alters immune cell
populations in SAVI mice
Wepreviously found thatabTcells are required for severe lungdis-
ease in SAVI mice (Luksch et al., 2019), so we hypothesized that
treatment with the VNA antibiotics cocktail may alter immune cell
populations. Treatment of SAVI mice with oral antibiotics
increased thepercent of naive T cellswhile decreasing the percent
and number of T effector cells (Figure S3). However, these rela-
tively small alterations in T cell populations do not necessarily
explain the near-complete elimination of lung disease in SAVI ani-
mals. Because bacterial CDNs can regulate numbers of myeloid
cell populations in the peritoneum and the spleen (Karaolis et al.,
2007), we reasoned that depletion of gut microbes may have the
opposite effect on myeloid cell populations in mice. Indeed, we
found that the VNA antibiotics cocktail led to a 4-fold decrease
in the number of dendritic cells (CD11c+ MHCII+), a 2-fold
decrease in inflammatory monocytes (CD11b+ Ly6Chi), and a
3-fold reduction in neutrophils (CD11b+ Ly6G+) in the spleens
ofSAVI, but notWT littermatecontrol animals (FigureS4).Although
certain antibiotics have the capacity to alter immune cell popula-
Figure 3. VNA treatment reduces pro-in-
flammatory cytokines, chemokines, and
Th1 cytokine levels in the lungs of SAVImice
Four-week-old STING N153S (SAVI) mice were
administered VNA cocktail or vehicle control ad
libitum and euthanized at 12 weeks.
(A–C) Cytokine and chemokine levels were as-
sessed by a BioPlex assay of lung homogenates.
Data represent the mean ± SEM of n = 5–8
biological replicates group,whichwere pooled from
2 independent experiments. Results were analyzed
by Mann-Whitney test. *p < 0.05; **p < 0.01.
tions via effects on hematopoiesis (Josefs-
dottir et al., 2017), we observed changes
only in SAVI mice and not in WT littermate
control animals, suggesting a specific ef-
fect of antibiotics in STING N153S gain of
function. These results are consistent
with the idea thatSTINGN153S ishyperre-
sponsive to bacterial CDNs.
Gut anaerobes but not germ-free
conditions can prevent STING-
associated autoinflammatory lung
disease in mice
Because the VNA antibiotics cocktail
nearly eliminates lung disease in SAVI
mice, we hypothesized that deleterious
bacteria are required to induce autoimmu-
nity, and that autoinflammatory lung dis-
ease would not develop in the absence of
commensal microbes. To test whether
commensal microbes are required for
lung disease, we generated germ-free SAVI mice. At 4 weeks of
age, we recolonized half of the germ-free SAVI animals with stool
from mice housed under enhanced specific-pathogen-free
(ESPF) conditions. Because antibiotics prevent lung disease in
SAVI mice, we anticipated that germ-free SAVI animals would
not develop lung disease. Unexpectedly, we found that germ-
free SAVI mice still develop severe lung disease. Indeed, the
severity of disease was the same in re-colonized and germ-free
SAVImice, demonstrating that complete elimination of commensal
bacteria does not prevent lung disease (Figures 4A and 4B).
The VNA antibiotics cocktail would not be expected to elim-
inate all commensal microbes, especially because these anti-
biotics would not fully eradicate anaerobic bacteria. For
example, we used a pan-bacteroides PCR assay to confirm
that at least some Bacteroides species likely persist after
treatment with VNA (data not shown). Because germ-free
SAVI mice develop severe autoinflammatory lung disease,
we reasoned that some of these gut anaerobes not sensitive
to VNA might protect against STING-associated lung disease.
To determine whether the protective factor is transferrable, we
performed a fecal transplant of stool from VNA-treated SAVI
animals into germ-free SAVI mice using stool from VNA-
treated SAVI animals. Two weeks after recolonization, we




histologically examined lungs and found that recolonization
using microbes from antibiotics-treated mice resulted in pre-
vention of autoinflammatory lung disease in SAVI animals (Fig-
ures 4A and 4B). Recolonization with stool from VNA antibi-
otics-treated mice also led to a reduction in expression of
Ifit1, Cxcl10, Isg15, and Tnfa, but not Il10 or Tgfb1 compared
with control microbiota recolonized mice (Figures 4C–4H).
However, unlike antibiotics treatment, germ-free conditions
had no effect on numbers or subsets of lymphoid and myeloid
cell populations other than a small increase in CD11b+ F4/80+
myeloid cells in recolonized animals (Figure S5). Similarly,
recolonization with VNA-treated microbes had no effect on
immune cells in SAVI animals (Figure S6). Thus, although bac-
teria are not required for lung disease pathogenesis in SAVI
mice, transplant of gut microbiota from VNA antibiotics-
treated animals almost completely protects against STING-
associated autoinflammatory lung disease.
Because the VNA antibiotics cocktail spares some gut anaer-
obes that are sensitive to metronidazole, we hypothesized that
Figure 4. Transplant of stool from VNA anti-
biotics-treated mice into germ-free SAVI
mice nearly eliminates STING-associated
lung disease
Germ-free, co-housed WT and STING N153S
(SAVI) micewere recolonized with stool from either
untreated STING N153S mice or VNA-treated
STING N153S mice.
(A) Representative hematoxylin and eosin-stained
images of lung sections from age-matched 12- to
13-week-old STING N153S mice and littermate
control mice. Top panel images were taken under
low magnification, and bottom panel images were
takenunder highmagnification. Scale bars: 100 mm.
(B) Quantitation of affected lung area of STING
N153Smice with or without recolonization.
(C–H) Gene expression of ISGs, cytokines, and
chemokines with or without recolonization. Data
represent the mean ± SEM of n = 8–16 mice per




mediate protection against STING-asso-
ciated autoimmunity. Indeed, addition of
metronidazole to the VNA cocktail
eliminated the protective effect of those
antibiotics (Figure 5). This suggests that
metronidazole-sensitive microbes can
protect against STING-associated auto-
inflammatory lung disease in mice.
An isolated presence of
Bacteroidales is associated with
protection against STING-
associated lung disease in mice
Because protozoa are susceptible to
metronidazole, we considered that the
protective, metronidazole-sensitive
microbe might be eukaryotic. However, 18S analysis of stool
from VNA-treated and untreated SAVI mice revealed no differ-
ences in the composition of the eukaryotic gut microbiota (Fig-
ure S7). Subsequent metagenomic analysis of stool from re-
colonized and germ-free animals revealed a dramatically
reduced number of bacterial reads in germ-free animals, as
well as in germ-free mice recolonized with microbiota from
mice treated with the VNA antibiotics cocktail (Figure 6A), while
recolonization with control gut microbiota resulted in a popula-
tion of commensals similar to that of ESPF mice (Figures 6A
and 6B). Shotgun metagenomic data of ESPF samples were
concordant with 16S results (Figure S2A), reflecting classifica-
tion of prior Porphyromonadaceae as Muribaculaceae in more
recently updated databases (Lagkouvardos et al., 2016). In
contrast, the relatively sparsely populated gut of recolonized
mice that received microbiota from antibiotics-treated mice
demonstrated a predominance of metronidazole-sensitive an-
aerobes of the order Bacteroidales, including gut anaerobes
such as Muribaculum (Figures 6C and 6D). Collectively, these




results suggest that a relative enrichment of Bacteroidales,
combined with depletion of other gut bacteria, may protect
against STING-associated autoinflammatory lung disease.
Recolonization with B. theta protects against
autoinflammatory lung disease in SAVI animals
To confirm that bacteria from the order Bacteroidales can pro-
tect against lung disease in SAVI mice, we recolonized VNAM-
treated SAVI mice with B. theta as a representative species for
Bacteroidales and histologically assessed perivascular lung
inflammation 2 weeks after recolonization. We discovered that
recolonization withB. thetawas sufficient to reduce lung disease
in SAVI mice (Figures 7A and 7B). Gene expression analysis of
select ISGs and cytokines revealed a 2-fold reduction in Il10,
as well as trends toward diminished expression of Cxcl10 and
Ifit1 (Figures 7C–7G). These data confirm the capacity of a Bac-
teroides species to protect against autoinflammatory lung dis-
ease in SAVI animals.
The short-chain fatty acids propionate and butyrate can
protect against STING-associated lung disease
Short-chain fatty acids serve as an energy source for bacteria
(Xie et al., 2009) but also have the capacity to regulate host im-
mune responses (Arpaia et al., 2013; Meyer et al., 2020). Many
bacterial species from the genus Bacteroides produce short-
chain fatty acids, including propionate (Reichardt et al., 2014),
and species of genus Muribaculum also are equipped with
fermentation pathways to produce propionate (Smith et al.,
2019). Since recolonization with B. theta protects against severe
autoinflammatory lung disease, we hypothesized that treatment
with short-chain fatty acids would protect against lung disease in
SAVI animals. We found that treatment with propionate and
butyrate led to a decrease in STING-associated autoinflamma-
tory lung disease, highlighting a potential role for short-chain
fatty acids produced by Bacteroidales (Figures 7H and 7I).
Short-chain fatty acids derived from anaerobesmight be onemi-
crobial factor that mediates protection against STING-associ-
ated autoinflammatory lung disease.
DISCUSSION
STING gain of function causes severe lung disease in patients
with SAVI. Because STING responds to bacteria-derived CDN li-
gands, we tested whether bacteria contribute to autoinflamma-
tory disease pathogenesis in a mouse model of SAVI. Unexpect-
edly, we discovered that STING gain of function causes
autoinflammatory lung disease in germ-free animals that lack
commensal microbes. In addition, we discovered that modu-
lating the composition and abundance of commensal microbes
almost completely eliminates systemic autoimmunity in SAVI
mice. Furthermore, transfer of metronidazole-sensitive Bacteroi-
dales bacteria to germ-free SAVI animals was associated with
protection against STING-associated lung disease.
Liu et al. (2014) found that SAVI patient fibroblasts with STING
gain-of-function mutations are hyperresponsive to CDNs. We
previously found that STING gain-of function mice develop auto-
immunity, T cell cytopenia, and lung disease independently of
the endogenous STING ligand cGAMP. Here, we found that
STING N153S BMDMs are hyperresponsive to the bacterial
STING ligand c-di-GMP, and so we hypothesized that bacterial
CDNs may be responsible for lung disease in SAVI animals.
However, our discovery that germ-free SAVI mice still develop
autoinflammatory lung disease revealed that bacterial CDNs
are not required for STING-associated autoimmunity. Neverthe-
less, we cannot exclude the possibility that bacterial CDNs may
influence disease severity in SAVI, perhaps in ways that were
beyond our ability to detect.
That gut microbes influence autoinflammatory lung disease
confirms the presence of a gut-lung axis in a model of SAVI.
How gut microbes influence autoimmunity in the lung is less
clear. Organs previously thought to be sterile or relatively sterile
have their own distinct microbial populations (Harris et al., 2007).
These distinct microbial communities do not exist in isolation
and can influence the microbiota in other organs (Bassis et al.,
2015). Some have speculated that a gut-lung axis exists, such
that intestinal and pulmonary environments can influence each
other (Cait et al., 2018; Trompette et al., 2014). For example,
Cooke et al. (2000) suggested a role for gut-derived
Figure 5. Metronidazole eliminates the
lung-protective effects of other antibiotics
Ten-week-old STING N153S (SAVI) mice were
administered a VNA cocktail or vehicle control ad
libitum and euthanized at 12 weeks.
(A) Representative hematoxylin and eosin-stained
images of lung sections from age-matched 12-
week-old STING N153S mice. Top panel images
were taken under low magnification, and bottom
panel images were taken under high magnifica-
tion. Scale bars: 100 mm.
(B) Quantitation of affected lung area of STING
N153S mice following administration of VNA or
control. Data represent the mean of n = 9–12 mice
per group, pooled from 3 independent experi-
ments. Results were analyzed by Mann-Whitney
test. **p < 0.01; ***p < 0.001.
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lipopolysaccharide in modulating immune cell populations and
inflammatory mediators in the lung during idiopathic pneumonia
syndrome after bone marrow transplantation. Trompette et al.
(2014) found that altering the ratio of Firmicutes to Bacteroidetes
led to a reduction in Th2 responses and protection against
allergic airway inflammation. Others have found that treatment
with antibiotics that deplete gut microbes can alter vulnerability
to bacterial infections of the lung (Robak et al., 2018; Schuijt
et al., 2016). Segmented filamentous bacteria (SFB) can induce
lung inflammation in transgenic mice expressing dual SFB-spe-
cific T cell receptors (TCRs) (Bradley et al., 2017), indicating that
lung inflammation can be initiated by antigen-specific T cells
directed against a gut microbe. Unlike other studies, which
were primarily focused on the role of gut microbes in regulating
infection or allergic inflammation, our work reveals a role for
gut microbes in regulating autoinflammation in a lung disease
caused by a human disease-associated mutation. Furthermore,
in contrast with the work of Trompette et al. (2014), our data do
not suggest any alteration in Th2 cytokines in association with
the reduction in lung disease (Figure 3). This suggests that the
mechanism of protection in our model of STING-associated
autoimmunity is distinct from that which was shown in a different
model of lung disease.
We found that antibiotics caused alterations in myeloid and
lymphoid cell populations, and that those effects could not be
transferred by recolonization of germ-free mice. However, we
cannot exclude the possibility that antibiotics also have
microbe-independent effects on immune cells (Gopinath et al.,
2018), which may protect against lung disease in SAVI animals.
Nevertheless, transfer of microbes into germ-free animals was
protective evenwithout appreciably altering immune cell popula-
tions. Without our germ-freemouse studies, wemight have been
misled to speculate that commensal microbes were required for
STING-associated autoinflammatory lung disease. Our results
underscore the value of studies in germ-free and recolonized
animals.
Anaerobes regulate immunity in other models of autoimmu-
nity, including experimental autoimmune encephalomyelitis
(EAE). For example, Bacteroides fragilis produces molecules
including polysaccharide A, which can promote expression of
anti-inflammatory cytokine IL-10 and protect against demyelin-
ation in EAE (Ochoa-Repáraz et al., 2010). Lactobacillus reuteri
also can suppress EAE (He et al., 2019). In other instances, bac-
terial metabolites such as short-chain fatty acids can modulate
immunity and reduce allergic inflammation in the lung (Tromp-
ette et al., 2014). Because STING-associated lung disease is
primarily mediated by ab T cells, one reasonable hypothesis
is that a gut anaerobe metabolite mediates the protective ef-
fect. Indeed, we confirmed that the short-chain fatty acids pro-
pionate and butyrate, which are common metabolites pro-
duced by anaerobes, can inhibit lung disease in SAVI
animals. However, our results also suggest that metronida-
zole-sensitive anaerobes protect against STING-associated
autoimmunity only upon depletion of bacteria sensitive to
VNA. This implies that protective effects of anaerobes can be
inhibited by VNA-sensitive bacteria. The precise roles and mo-
lecular mechanisms of these microbial community interactions
remain to be determined.
Metagenomic analysis on animals recolonized with stool
from VNA antibiotics-treated SAVI mice revealed several
anaerobic species from the order Bacteroidales, most spe-
cies of which have not been characterized. In recent years,
Muribaculaceae species, such as Muribaculum intestinale,
were identified as a core component of the commensal mi-
crobiome of several homeothermic species (Ormerod et al.,
2016). However, little is known about M. intestinale outside
of its existence as a commensal microorganism, and even
less is known about many of the other Bacteroidales species
that are enriched in mice recolonized with stool from VNA an-
tibiotics-treated animals. Whether these bacterial popula-
tions have the capacity to modulate other autoimmune dis-
eases has not been investigated. Recolonization with
B. theta, which we chose as a representative species of Bac-
teroidales, was sufficient to diminish the severity of autoin-
flammatory lung disease in SAVI animals. Although treatment
with VNA antibiotics led to the relative enrichment of several
Bacteroidales species bacteria, our finding provides evi-
dence that a single species can modulate perivascular
inflammation in the lung, although the immunological mecha-
nism has not yet been elucidated.
Commensal bacteria of the order Bacteroidales can produce
short-chain fatty acids (Reichardt et al., 2014). We found that
treatment of SAVI mice with the short-chain fatty acids propio-
nate or butyrate can protect against STING-associated autoin-
flammatory lung disease, and that elimination of lung disease
was associated with isolated colonization with Bacteroidales.
Production of immune-modulating short-chain fatty acids might
be one of several mechanisms by which relative enrichment of
certain bacterial species can protect against autoinflammatory
lung disease in SAVI animals. Short-chain fatty acid receptors
GPR41 and GPR43 are expressed on immune cells (Maslowski
et al., 2009; Sina et al., 2009) and modulate inflammatory
Figure 6. VNA-recolonized SAVI mice have a reduction in bacterial reads compared with ESPF and control recolonized mice and an
outgrowth of Bacteroidales not found in germ-free samples
Ten-week-old STING N153S (SAVI) mice were recolonized with stool from VNA-treated STING N153S animals or left germ-free, and stool was collected at
12 weeks.
(A) Bacterial family reads obtained from metagenomic sequencing of stool DNA from ESPF, control recolonized, VNA-recolonized, or germ-free STING N153S
mice.
(B) Bacterial family relative abundance obtained from metagenomic sequencing of stool DNA from ESPF, control recolonized, VNA-recolonized, or germ-free
STING N153S mice.
(C) Bacterial species reads obtained from metagenomic sequencing of stool DNA from VNA-recolonized or germ-free STING N153S mice.
(D) Bacterial species relative abundance obtained frommetagenomic sequencing of stool DNA from VNA-recolonized or germ-free STING N153S mice. Species
unique to VNA-recolonized samples are shown in boldface. Data represent samples collected from n = 3 mice per condition pooled from 2 independent ex-
periments.




responses through inhibition of histone deacetylase activity.
Nevertheless, our studies did not definitively elucidate an immu-
nological mechanism by which antibiotics modulate autoinflam-
matory lung disease in SAVI mice. An alternative hypothesis is
that specific bacterial populations may produce small-molecule
antagonists of STING that specifically modulate inflammatory re-
sponses in our model of STING-associated autoimmunity.
Further characterization of protective gut anaerobes, including
characterization of potentially protective metabolites, may lead
to novel therapies for the treatment of SAVI and other autoim-
mune diseases associated with hyperactivation of the STING
pathway.
Figure 7. Recolonization with Bacteroides thetaiotaomicron and treatment with propionate and butyrate protect against STING-associated
lung disease in mice
Ten-week-old co-housed WT and STING N153S (SAVI) mice were recolonized with either B. theta or vehicle control.
(A) Representative hematoxylin and eosin-stained images of lung sections from age-matched 12- to 13-week-old STINGN153Smice and littermate control mice.
Top panel images were taken under low magnification, and bottom panel images were taken under high magnification. Scale bar: 100 mm.
(B) Quantitation of affected lung area of STING N153S mice with or without recolonization.
(C–G) Gene expression of ISGs, cytokines, and chemokineswith or without recolonization. Data represent themean ±SEM of n = 5–6mice per group pooled from
2 independent experiments and were analyzed usingMann-Whitney test. Ten-week-old co-housedWT and STINGN153Smice were given vehicle control, 1 mg/
kg propionate, or 1 mg/kg butyrate daily for 2 weeks via intraperitoneal injection and were euthanized at 12 weeks.
(H) Representative hematoxylin and eosin-stained images of lung sections from age-matched 12-week-old STINGN153Smice and littermate control mice. Scale
bars: 100 mm.
(I) Quantitation of affected lung area of STING N153S mice following administration of propionate or vehicle control.
Data in (H) and (I) represent themean of n = 6–12mice per group pooled from 2 independent experiments. Data were analyzed usingMann-Whitney test. *p < 0.05;
**p < 0.01.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse anti-CD3 Biolegend RRID:AB_2562555
Mouse anti-CD4 Biolegend RRID:AB_2562557
Mouse anti-CD8a Biolegend RRID:AB_2075239
Mouse anti-CD11b Biolegend RRID:AB_2629529
Mouse anti- CD11c Biolegend RRID:AB_389306
Mouse anti-CD19 Biolegend RRID:AB_312825
Mouse anti-CD45 Biolegend RRID:AB_2650656
Mouse anti-F4/80 Biolegend RRID:AB_893481
Mouse anti-I-A/I-E Biolegend RRID:AB_313323
Mouse anti-Ly6C Biolegend RRID:AB_2562177
Mouse anti-Ly6G Biolegend RRID:AB_2616999
Mouse anti-NK-1.1 Biolegend RRID:AB_2783136
Bacterial and virus strains
Bacteroides thetaiotaomicron ATCC Cat# 29148
Chemicals, peptides, and recombinant proteins
Vancomycin hydrochloride Sigma-Aldrich Cat# V2002
Neomycin trisulfate salt hydrate Sigma-Aldrich Cat# N1876
Ampicillin sodium salt Sigma-Aldrich Cat# A9518
Metronidazole Sigma-Aldrich Cat# M1547
Dulbecco’s phosphate buffered saline ThermoFisher Cat# 14190136
Paraformaldehyde 20% solution, EM grade Electron Microscopy Sciences Cat# 15713-S
Butyric acid sodium salt Sigma-Aldrich Cat# 303410
Sodium propionate Sigma-Aldrich Cat# P1880
Critical commercial assays
Bio-Plex Pro Mouse Cytokine 23-Plex
Assay
Bio-Rad Cat# M60009RDPD
DNeasy 96 Blood and Tissue Kit QIAGEN Cat# 69581
QIAamp Fast DNA Stool Mini Kit QIAGEN Cat# 51604
Nextera DNA Library Prep Kit Illumina Cat# 20018795
RNeasy Mini Kit QIAGEN Cat# 74106
TaqMan RNA-to-Ct 1-step kit Applied Biosystems Cat# 4392653
Deposited data
16S and Metagenomics data European Nucleotide Archive
PRJEB42379
Experimental models: Organisms/strains
Mouse: STING N153S mice Jackson Laboratory Stock# 033543
Mouse: Germ-free STING N153S mice This paper N/A
Oligonucleotides
Cxcl10 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.43575827
Gapdh PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.39a.1
Ifit1 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.32674307
Isg15 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.41476392
Il6 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.10005566
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jonathan
J. Miner (miner@wustl.edu).
Materials availability
This study did not generate new unique reagents. Commercially available reagents are indicated in the Key resources table.
Data and code availability
The accession numbers for the rDNA and metagenomic sequencing data reported in this paper are European Nucleotide Archive:
PRJEB42379
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All protocols for animal studies were approved by the Institutional Animal Care and Use Committees at the Washington University
School of Medicine (assurance no. A-3381-01). Mice were housed in specific-pathogen-free mouse facilities at the Washington
University School of Medicine. STING N153S mice (SAVI mice) were generated on a C57BL/6 background using CRISPR/Cas9
as previously described (Warner et al., 2017). In all experiments using SAVI mice, co-housed WT littermates were used as controls.
Germ-free and recolonized mice were housed in the gnotobiotic mouse facility at the Washington University School of Medicine.
Confirmation of a germ-free environment is done by bi-weekly wet mount observation, anaerobic and aerobic culture, fungal culture,
and monthly 16S and Transnetyx sequencing. For recolonization studies, co-housed WT and SAVI mice in ESPF conditions were
given the VNA cocktail or Kool-Aid in drinking water for two weeks. At the end of two weeks, fecal pellets from VNA- or Kool-Aid-
treated SAVI animals were collected, then pooled and homogenized anaerobically into a liquid mixture. Germ-free WT and SAVI
mice were recolonized by oral gavage with the anaerobic mixtures or left germ-free for two weeks. At the two week time point,
mice were sacrificed, and stool, lungs, and spleen were collected for subsequent processing. For Bacteroides thetaiotaomicron re-
colonization studies, WT and SAVI mice were given the VNAM cocktail in drinking water for two weeks. After stopping treatment for
one day, mice were given 13 108 CFU B. theta or vehicle control via oral gavage. Two days later, the mice were given a second oral
gavage of 13 108 CFUB. theta or vehicle control. Twoweeks after recolonization, micewere sacrificed and organswere collected for
subsequent processing. Power analysis was conducted for Institutional Animal Care and Use Committee-approved in vivo studies in
order to determine the number of animals needed per experimental group. At least two independent experiments were conducted to
replicate findings. No outliers were excluded from analyses. Approximately equal numbers of both sexes were used. The age and
number of animals used for each experiment is listed in the figure legends.
Bone marrow-derived macrophages
Bone marrow-derived macrophages (BMDMs) were generated from bone marrow cells flushed from the femurs and tibias of age-
matched SAVI mice, WT littermates, and STINGGoldenticket mice. Then 2.53 106 cells were incubated at 37C in 10-cm cell culture
plates in complete medium containing Dulbecco’s modified Eagle medium (DMEM) (catalog no. D6429; Sigma), 10% fetal
bovine serum (FBS) (catalog no. SH30070-03; HyClone), 1% penicillin and streptomycin (catalog no. 15140; GIBCO), 1% sodium
pyruvate (catalog no. 11360; GIBCO), and 1%L-glutamate (catalog no. 35050; GIBCO), supplementedwith 40 ng/mL ofmacrophage
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Il10 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.13531087
Tnfa PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.12575861
Tgfb1 PrimeTime qPCR Assay Integrated DNA Technologies Mm.PT.58.11254750
Software and algorithms
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
GraphPad Prism 8 GraphPad https://www.graphpad.com
FlowJo FlowJo https://www.flowjo.com
Microbial Ecology software (QIIME, version
1.8.0)
QIIME http://qiime.org/
BBTools v38.26 BBTools https://jgi.doe.gov/data-and-tools/bbtools/
One Codex Database One Codex https://www.onecodex.com/




colony-stimulating factor (M-CSF) (catalog no. 300-25; PeproTech), for 6 days. On day 7, BMDMs were replated and thereafter were
cultured in complete medium with 20 ng/mL of M-CSF. Cells from approximately equal numbers of both sexes were used.
METHOD DETAILS
Histologic staining analysis
Mice were perfused with 20 mL of PBS, then lung samples were isolated from mice, fixed in 4% paraformaldehyde for 48 hours at
room temperature, and suspended in 70% ethanol before being embedded in paraffin. Tissue sections (thickness of 5 mm) were
stained with hematoxylin and eosin, followed by image acquisition using a Nikon Eclipse E400 microscope and NIS Elements
software. Using ImageJ software (Schneider et al., 2012), lung lesions were encircled by a blinded researcher, who quantitated
the number of pixels within lung lesions divided by the total number of pixels in the lung tissue, excluding large airway spaces.
For colon histology, the entire length of the colon was removed from mice and gently flushed with 5 mL of PBS, followed by 5 mL
of 4% paraformaldehyde with blunt tipped needles. Next, scissors were used to cut a straight line along the length of the colon.
With epithelial layer facing up, colon samples were pinned out and fixed in 4% paraformaldehyde for 16h at room temperature.
The fixed tissue was washed with 70% ethanol three times and then embedded in 2% agar, followed by paraffin embedding,
sectioning, and hematoxylin and eosin staining.
Flow cytometry
Spleens were crushed and filtered through a 70-um cell strainer to generate single-cell suspensions. Cells were incubated with an-
tibodies in PBS/4% FBS for 30minutes, including fluorescently-conjugated antibodies specific for CD3, CD4, CD8a, CD11b, CD11c,
CD19, CD45, F4/80, Ly6C, Ly6G, MHCII, and NK1.1 (All antibodies from BioLegend). Next, splenocytes were washed twice with
PBS/4% FBS and analyzed on a BD FACS Canto II or Thermo Fisher Scientific Attune NxT Flow Cytometer. Flow cytometry data
were analyzed with FlowJo software.
Multiplex cytokine assay
Lungs were harvested and homogenized in 200 mL of PBS. Cytokine and chemokine levels were measured with the Bio-Plex Pro
Mouse Cytokine Group I Panel 23-Plex Assay Kit (Bio-Rad Laboratories, Hercules, California) on a Luminex platform. Twenty-three
cytokines and chemokines were examined.
16S rDNA sequencing and analysis
Fecal pellets were collected from co-housed WT and SAVI mice and stored at 80C. DNA was extracted from fecal pellets using
phenol:chloroform and purified using the DNeasy Blood and Tissue Kit. (QIAGEN) per manufacturer’s instructions. Primer selection
and PCRs were performed as described previously (Caporaso et al., 2011). Samples were amplified in triplicate using Golay-bar-
coded primers specific to the V4 region within the 16S rRNA gene. Amplified samples were then consolidated, and sample quality
was determined using gel electrophoresis. Platinum High-Fidelity Taq (Invitrogen) was used to amplify genomic DNA by PCR and
amplicons were pooled and purified using 0.6x Agencourt Ampure XP beads (Beckman-Coulter) according to the manufacturer’s
instructions, and quantitated using Qubit (ThermoFisher). The DNA pool was then sequenced using the Illumina MiSeq platform.
Sequencing data was analyzed using Quantitative Insights into Microbial Ecology software (QIIME, version 1.8.0) (Caporaso et al.,
2010).
18S sequencing and analysis
Fecal pellets were collected from co-housed WT and SAVI mice following two-week administration of VNA or Kool-Aid in drinking
water. Samples were stored at 80C. DNA was extracted using the QIAamp Fast DNA Stool Mini Kit (QIAGEN) and submitted to
CD Genomics for 18S sequencing and data analysis.
Metagenomic sequencing and analysis
Fecal pellets were collected from germ-free mice and mice recolonized with stool from VNA-treated SAVI mice. Fecal samples were
stored at80C. DNA was extracted from fecal pellets using phenol:chloroform and purified using the DNeasy Blood and Tissue Kit.
(QIAGEN) per manufacturer’s instructions. Next, we performed tagmentation on the samples, followed by purification using 0.6x
Agencourt Ampure XP beads (Beckman-Coulter) according to the manufacturer’s instructions. Samples were prepared for shotgun
sequencing using amodified version of a previously described protocol (Baymet al., 2015) andmakes use of the Nextera DNA Library
Prep Kit (Catalog # FC-121-1030/1031). Raw sequencing reads were quality filtered and trimmed using BBTools v38.26. Samples
then had any PhiX contamination removed and were screened against the mouse reference genome to remove any host reads.
Paired-end readswere then interleaved into a single file for analysis. Sampleswere then uploaded to theOneCodex analysis platform
and screened against the One Codex Database. Differences between samples were first examined at the Family level selecting any
taxa with > 0.1% Relative Abundance. Germ-free and VNA Re-colonized mice were compared at the Species level with the same
cutoffs.





Total RNA from lung homogenates or BMDMswas isolated using the RNeasy kit (QIAGEN) per the manufacturer’s protocol. TaqMan
RNA-to-Ct 1-step kit (Applied Biosystems) was used to measure mRNA expression. Primer and probe assays were obtained from
Integrated DNA Technologies.DDCt values were calculated and then normalized to the untreatedWT samples. All samples analyzed
were normalized to the house keeping gene (GAPDH). Samples where the target gene did not amplify were assigned a CT value of 38
as the limit of detection.
Short-chain fatty acid treatment
Propionate and butyrate solutionswere prepared in sterile PBS. Co-housed,WT and SAVImicewere given either PBS, propionate, or
butyrate at a concentration of 1 mg/kg body weight and volume of 200 mL via intraperitoneal injection. Mice were injected daily for
14 days and euthanized on day 14. Lungs were fixed and submitted for H&E staining.
QUANTIFICATION AND STATISTICAL ANALYSIS
All data were analyzed using GraphPad Prism software by Mann-Whitney test as specified in the figure legends.
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Figure S1. Lung disease recurs after stopping treatment of SAVI mice with the VNA antibiotics 
cocktail. Related to Figure 2. Four-week-old STING N153S (SAVI) mice were administered VNA or 
vehicle control ad libitum, switched to normal drinking water at eight weeks, and euthanized at twelve 
weeks. (A) Representative hematoxylin and eosin-stained images of lung sections from age-matched 12-
week-old STING N153S mice and littermate control mice. Upper panel images were taken under low 
magnification, lower panel images were taken under high magnification. Scale bar = 100 µm. (B) 
Quantitation of affected lung area of STING N153S mice following administration of VNA or control. Data 
represent the mean of n = 5-6 mice per group pooled from 2 independent experiments. Results were 
analyzed by Mann-Whitney test. 
  
 
Figure S2. Co-housed SAVI and WT littermate mice have similar gut microbial compositions. 
Related to Figures 2 and 6. Twelve-week-old, co-housed WT and STING N153S (SAVI) mice were 
administered VNA or vehicle control ad libitum and stool was collected. 16S (A) and virome (B-E) analysis 
on stool samples collected from twelve-week-old, co-housed WT and STING N153S littermates. Data 
represent the mean +/- SEM of samples collected from n = 7-19 co-housed WT and STING N153S 
animals per genotype pooled from 3 independent timepoints. Results were analyzed by Mann-Whitney 
test.  
 
Figure S3. Treating mice with the VNA antibiotic cocktail alters T-cell populations in SAVI animals. 
Related to Figures 2 and 3. Four-week-old STING N153S (SAVI) mice were administered vancomycin, 
neomycin, and ampicillin cocktail (VNA) or vehicle control ad libitum and euthanized at twelve weeks. (A) 
Representative FACS plots of WT (left panels) and STING N153S (right panels) CD45+CD3+CD4+ cells. 
Cell frequencies within each gate are denoted in red. (B-E) Percent and total number of naïve CD4+ T 
cells (CD44-CD62L+) and effector CD4+ T cells (CD44+CD62L-). (F) Representative FACS plots of WT 
(left panels) and STING N153S (right panels) CD45+CD3+CD8+ cells. Cell frequencies within each gate 
are denoted in red. Percent and total number of naïve CD8+ T cells (CD44-CD62L+) and effector CD8+ T 
cells (CD44+CD62L-). Data represent the mean +/- SEM of results from n = 5-8 mice per group, and were 
pooled from 2 independent experiments. Results were analyzed by Mann-Whitney test. *, P < 0.05; **, P 
< 0.01.  
Figure S4. Treatment with the VNA antibiotics cocktail reduces myeloid populations in SAVI but 
not WT littermate control animals. Related to Figures 2 and 3. Four-week-old STING N153S (SAVI) 
mice were administered vancomycin, neomycin, and ampicillin cocktail (VNA) or vehicle control ad libitum 
and euthanized at twelve weeks. Representative FACS plots of WT (left panels) and STING N153S (right 
panels) (A) CD45+Ly6G+ and CD45+Ly6G- cells, (B) CD45+CD11c+MHCII+ cells, and (C) 
CD45+CD11b+Ly6C+ cells. Cell frequencies within each gate are denoted in red. (D-I) Percent and total 
number of CD11c+ dendritic cells (CD11c+MHCII+), inflammatory monocytes (CD11b+Ly6Chi), and 
neutrophils (Ly6G+). Data represent the mean +/- SEM of samples analyzed from n = 5-8 mice per group, 
which were pooled from 2 independent experiments. Results were analyzed by Mann-Whitney test. *, P 
< 0.05; **, P < 0.01. 
Figure S5. Germ-free and recolonized conditions lead to similar effector T-cell and myeloid 
populations in SAVI animals. Related to Figure 4. Ten-week-old STING N153S (SAVI) mice were 
recolonized with stool from untreated STING N153S animals or left germ-free and euthanized at twelve 
weeks. (A-D) Percent and total number of naïve CD4+ T cells (CD44-CD62L+) and effector CD4+ T cells 
(CD44+CD62L-). (E-H) Percent and total number of naïve CD8+ T cells (CD44-CD62L+) and effector CD8+ 
T cells (CD44+CD62L-). (I-P) Percent and total number of CD11c+ dendritic cells (CD11c+MHCII+), 
inflammatory monocytes (CD11b+Ly6Chi), and neutrophils (Ly6G+). Data represent the mean +/- SEM of 
samples analyzed from n = 7-12 mice per group, which were pooled from 2 independent experiments. 
Results were analyzed by Mann-Whitney test. *, P < 0.05; **, P < 0.01. 
 
Figure S6. Germ-free conditions and recolonization with stool from VNA antibiotics-treated lead 
to similar effector T cell and myeloid populations in SAVI animals. Related to Figure 4. Ten-week-
old STING N153S (SAVI) mice were recolonized with stool from VNA-treated STING N153S animals or 
left germ-free and euthanized at twelve weeks. (A-D) Percent and total number of naïve CD4+ T cells 
(CD44-CD62L+) and effector CD4+ T cells (CD44+CD62L-). (E-H) Percent and total number of naïve CD8+ 
T cells (CD44-CD62L+) and effector CD8+ T cells (CD44+CD62L-). (I-P) Percent and total number of 
CD11c+ dendritic cells (CD11c+MHCII+), inflammatory monocytes (CD11b+Ly6Chi), and neutrophils 
(Ly6G+). Data represent the mean +/- SEM of n = 4-15 mice group pooled from 2 independent 




















Figure S7. Co-housed SAVI and WT littermate mice exhibit similar eukaryotic gut microbial 
compositions. Related to Figures 4 and 6. Twelve-week-old, co-housed WT and STING N153S (SAVI) 
mice were administered VNA or vehicle control ad libitum and stool was collected, followed by 18S 
sequencing and analysis. (A) Relative abundance of microbial families in individual stool samples. (B-C) 
Weighted and unweighted PCoA analysis of stool samples. (D) Heatmap demonstrating presence of 
microbial groups in individual samples. Data represent samples pooled from of n = 10 mice per genotype 
per condition with stool taken at 3 independent timepoints. 
